Endonovo Therapeutics Inc.’s (ENDV) Electroceuti
Post# of 416
(Total Views: 1051)
Posted On: 11/20/2019 3:49:24 PM
Endonovo Therapeutics Inc.’s (ENDV) Electroceutical Device Brings Rapid Pain Relief, Leads to 30-40% Decrease in Post-Surgical Narcotic Prescriptions
- Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-op
- SofPulse (R) use causes 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication and 50% less inflammation
- Bioelectric medicine is a $17 billion market, projected to exceed $33 billion annually by 2025
Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc.’s (OTCQB: ENDV) proprietary SofPulse(R) technology is being successfully used by surgeons at New Hanover Regional Medical Center (NHRMC) in North Carolina to reduce the volume of opioid prescriptions and remove the need for patients to take narcotics for pain after surgery.
According to a WECT.com report, NHRMC has been using SofPulse(R) for six months, during which medical staff noticed a 30-40 percent drop in post-op narcotic prescriptions (http://nnw.fm/V53Bc). The report quoted urologist Dr. Roc McCarthy as detailing several benefits of the technology, including faster recovery times and fewer people asking for pain medication.
The non-invasive SofPulse(R) device uses electromagnetic waves to reduce inflammation after surgery. It is the flagship product of Endonovo Therapeutics and its proprietary Electroceutical(R) Therapy, developed for the treatment of inflammation, cardiovascular disease, and central nervous system disorders such as traumatic brain injury (TBI), acute concussions, post-concussion syndrome, and multiple sclerosis.
According to McCarthy, many patients are receptive to the SofPulse(R) device and opt to use it instead of pain medication because they are worried about the side effects of opioids, including addiction risks in the context of the national opioid crisis. The opioid crisis has reached a peak in the country, putting intense pressure on pharmaceutical companies, health care providers, and medical facilities to reduce the use of painkillers. This has created demand for other viable pain control solutions, which were quite limited until recently.
While the technology behind SofPulse(R) isn’t new, it has not been fully developed until now, McCarthy added. “It’s just opening the door to a world of opportunity for people to come up and innovate other ways of decreasing the amount of pain that people are having,” he said.
SofPulse(R) has prospects to reduce the need and intake of prescription drugs over the long term. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. This is a positive development in light of 2010 data of the Department of Health and Human Services, according to which 31% of adverse events and 42% of temporary harm events among Medicare patients in acute care hospitals were related to medication.
According to Endonovo data, the technology leads to a 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication, and 50% less inflammation. SofPulse(R) works by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for recovery to occur (http://nnw.fm/0sDPQ).
Endonovo’s Electroceutical(R) Therapy is certified for the treatment of chronic wounds by the Centers for Medicare and Medicaid Services (CMS) nationwide. The success of this proprietary device is rapidly broadening the company’s horizons, providing them with new and unique opportunities to enter the buoyant bioelectric medicine market, which is currently worth $17 billion and projected to exceed $33.14 billion annually by 2025 (http://nnw.fm/BsW08).
Endonovo developed its SofPulse(R) technology in collaboration with researchers and medical centers. The wearable, non-invasive pain reducer continues to undergo testing as a way of limiting opioid use with emphasis on post-surgical pain relief and recovery. These technological developments represent massive, long-term valuation potential for the company.
For more information, visit the company’s website at www.Endonovo.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-op
- SofPulse (R) use causes 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication and 50% less inflammation
- Bioelectric medicine is a $17 billion market, projected to exceed $33 billion annually by 2025
Commercial-stage developer of innovative medical devices Endonovo Therapeutics Inc.’s (OTCQB: ENDV) proprietary SofPulse(R) technology is being successfully used by surgeons at New Hanover Regional Medical Center (NHRMC) in North Carolina to reduce the volume of opioid prescriptions and remove the need for patients to take narcotics for pain after surgery.
According to a WECT.com report, NHRMC has been using SofPulse(R) for six months, during which medical staff noticed a 30-40 percent drop in post-op narcotic prescriptions (http://nnw.fm/V53Bc). The report quoted urologist Dr. Roc McCarthy as detailing several benefits of the technology, including faster recovery times and fewer people asking for pain medication.
The non-invasive SofPulse(R) device uses electromagnetic waves to reduce inflammation after surgery. It is the flagship product of Endonovo Therapeutics and its proprietary Electroceutical(R) Therapy, developed for the treatment of inflammation, cardiovascular disease, and central nervous system disorders such as traumatic brain injury (TBI), acute concussions, post-concussion syndrome, and multiple sclerosis.
According to McCarthy, many patients are receptive to the SofPulse(R) device and opt to use it instead of pain medication because they are worried about the side effects of opioids, including addiction risks in the context of the national opioid crisis. The opioid crisis has reached a peak in the country, putting intense pressure on pharmaceutical companies, health care providers, and medical facilities to reduce the use of painkillers. This has created demand for other viable pain control solutions, which were quite limited until recently.
While the technology behind SofPulse(R) isn’t new, it has not been fully developed until now, McCarthy added. “It’s just opening the door to a world of opportunity for people to come up and innovate other ways of decreasing the amount of pain that people are having,” he said.
SofPulse(R) has prospects to reduce the need and intake of prescription drugs over the long term. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. This is a positive development in light of 2010 data of the Department of Health and Human Services, according to which 31% of adverse events and 42% of temporary harm events among Medicare patients in acute care hospitals were related to medication.
According to Endonovo data, the technology leads to a 500% increase in new blood vessels, 59% increase in surgical wound recovery, 57% reduction in pain at one-hour post-op, 55% less pain medication, and 50% less inflammation. SofPulse(R) works by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for recovery to occur (http://nnw.fm/0sDPQ).
Endonovo’s Electroceutical(R) Therapy is certified for the treatment of chronic wounds by the Centers for Medicare and Medicaid Services (CMS) nationwide. The success of this proprietary device is rapidly broadening the company’s horizons, providing them with new and unique opportunities to enter the buoyant bioelectric medicine market, which is currently worth $17 billion and projected to exceed $33.14 billion annually by 2025 (http://nnw.fm/BsW08).
Endonovo developed its SofPulse(R) technology in collaboration with researchers and medical centers. The wearable, non-invasive pain reducer continues to undergo testing as a way of limiting opioid use with emphasis on post-surgical pain relief and recovery. These technological developments represent massive, long-term valuation potential for the company.
For more information, visit the company’s website at www.Endonovo.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)